Inventiva raises $44M as it preps for a PhIII NASH program, upcoming IIb readout
French biotech Inventiva has raised about $44 million dollars from a group of venture backers lured by the potential of an upcoming late-stage effort on NASH. And one of those backers, Paris-based Sofinnova Partners, is funding the company out of a brand new crossover fund that launched about a week ago with $340 million.
The biotech’s pipeline is topped by lanifibranor (IVA337), designed to spur three PPAR (peroxisome proliferator-activated receptor) isoforms — α, δ and γ — in fighting NASH. It’s also being advanced for systemic sclerosis, a rare disease which triggers progressive organ failure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.